Key Points
- CEO Fred Aslan sold 61,696 Artiva Biotherapeutics shares at an average price of $6.84, generating $422,000.64. The sale was made to cover tax withholding tied to vested equity awards, leaving him with 1,543,069 shares.
- ARTV opened at $7.27 and remains well below its 50-day and 200-day moving averages of $10.02 and $9.23, respectively. The company reported a quarterly loss of $0.63 per share and analysts expect a full-year loss of $2.62 per share.
- Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $39.00, although ratings range from Strong Buy to Sell.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) COO Jennifer Bush sold 8,370 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $57,250.80. Following the transaction, the chief operating officer owned 366,159 shares in the company, valued at approximately $2,504,527.56. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Artiva Biotherapeutics Stock Up 2.0%
Shares of ARTV stock opened at $7.27 on Wednesday. The firm has a market cap of $355.43 million, a price-to-earnings ratio of -2.20 and a beta of 2.40. Artiva Biotherapeutics, Inc. has a 52-week low of $2.71 and a 52-week high of $14.53. The company's 50 day moving average is $10.02 and its 200 day moving average is $9.23.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.63). Analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.
Analysts Set New Price Targets
ARTV has been the subject of a number of analyst reports. Wall Street Zen upgraded Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $40.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Finally, HC Wainwright reissued a "buy" rating on shares of Artiva Biotherapeutics in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.
Read Our Latest Research Report on ARTV
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ARTV. State of Wyoming purchased a new position in Artiva Biotherapeutics during the second quarter valued at approximately $45,000. Squarepoint Ops LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $144,000. Spark Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $160,000. Dimensional Fund Advisors LP acquired a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth approximately $131,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Artiva Biotherapeutics during the 1st quarter valued at approximately $139,000.
Artiva Biotherapeutics Company Profile
(
Get Free Report)
Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.
Artiva's lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
